Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy1件: Bezafibrate1件: Bezafibrate 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 94 💬
2Bezafibrate 200 mg in addition to UDCA therapy1件: Bezafibrate1件: Bezafibrate 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
3Bezafibrate 400 mg in addition to UDCA therapy1件: Bezafibrate1件: Bezafibrate 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
4Standard of Care: UDCA----1件: 93 💬
5UDCA----2件: 93, 94 💬
6UDCA (Ursodeoxycholic acid)1件: Ursodeoxycholic acid (UDCA)1件: Ursodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬1件: 93 💬
7Ursodeoxycholic acid (UDCA)1件: Ursodeoxycholic acid (UDCA)1件: Ursodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬1件: 94 💬
8Ursodeoxycholic acid (UDCA) 500 mg1件: Ursodeoxycholic acid (UDCA)1件: Ursodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬1件: 46 💬
9Ursodiol (ursodeoxycholic acid, UDCA)1件: Ursodeoxycholic acid (UDCA)1件: Ursodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬1件: 97 💬